Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA “First Generics” Policy Not Enough, Mylan CEO Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency's ANDA review needs a top-to-bottom policy overhaul to end approval delays, Coury says.

You may also be interested in...



J&J Ditropan XL Goes Generic

Impax/Teva launching 15 mg strength, and Mylan joins with "authorized" generic as well as its own version of the 5 mg and 10 mg strengths.

J&J Ditropan XL Goes Generic

Impax/Teva launching 15 mg strength, and Mylan joins with "authorized" generic as well as its own version of the 5 mg and 10 mg strengths.

Mylan Undaunted By Other Duragesic Generics

Fentanyl patch competitors have yet to deliver the product dependably, says Mylan CEO.

Related Content

Topics

UsernamePublicRestriction

Register

PS063344

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel